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Background: Abnormal behaviors of young patients after taking the anti-influenza agent oseltamivir (Tamiflu®,
F. Hoffmann-La Roche, Ltd., Basel, Switzerland) have been suspected as neuropsychiatric adverse events (NPAEs).
Immune response to viral infection is suspected to cause elevation of drug concentration in the brain of
adolescents. In the present study, the effect of innate immune activation on the brain uptake of [11C]oseltamivir
was quantitatively evaluated in juvenile monkeys.
Methods: Three 2-year-old monkeys underwent positron emission tomography (PET) scans at baseline and
immune-activated conditions. Both scans were conducted under pre-dosing of clinically relevant oseltamivir. The
immune activation condition was induced by the intravenous administration of polyinosine-polycytidylic acid (poly I:C).
Dynamic [11C]oseltamivir PET scan and serial arterial blood sampling were performed to obtain [11C]oseltamivir kinetics.
Brain uptake of [11C]oseltamivr was evaluated by its normalized brain concentration, brain-to-plasma concentration
ratio, and plasma-to-brain transfer rate. Plasma pro-inflammatory cytokine levels were also measured.
Results: Plasma interleukin-6 was elevated after intravenous administration of poly I:C in all monkeys. Brain
radioactivity was uniform both at baseline and under poly I:C treatment. The mean brain concentrations of
[11C]oseltamivir were 0.0033 and 0.0035% ID/cm3 × kg, the mean brain-to-plasma concentration ratios were 0.58
and 0.65, and the plasma-to-brain transfer rates were 0.0047 and 0.0051 mL/min/cm3 for baseline and poly I:C
treatment, respectively. Although these parameters were slightly changed by immune activation, the change was
not notable.
Conclusions: The brain uptake of [11C]oseltamivir was unchanged by poly I:C treatment in juvenile monkeys.
This study demonstrated that the innate immune response similar to the immune activation of influenza would
not notably change the brain concentration of oseltamivir in juvenile monkeys.
Keywords: Positron emission tomography; Oseltamivir; Brain; Monkey; Poly I:C* Correspondence: suhara@nirs.go.jp
1Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1
Anagawa, Inage-ku, Chiba 265-8555, Japan
Full list of author information is available at the end of the article
© 2014 Seki et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Seki et al. EJNMMI Research 2014, 4:24 Page 2 of 10
http://www.ejnmmires.com/content/4/1/24Background
Oseltamivir (Tamiflu®, F. Hoffmann-La Roche, Ltd., Basel,
Switzerland) is the orally active ester prodrug of the anti-
influenza agent Ro 64-0802, a potent and selective viral
neuraminidase inhibitor that is effective for the treatment
of influenza A, B, and A (H1N1). Unusual neuropsychi-
atric events even including suicidal events in young pa-
tients taking oseltamivir have been reported in Japan [1].
Such incidents have been suspected as neuropsychiatric
adverse events (NPAEs) of oseltamivir, although the
underlying mechanisms have not yet been clarified.
Due to such issues, great efforts have been made to
elucidate the factors affecting oseltamivir penetration
into the central nervous system (CNS) in rodents and
nonhuman primates. It was elucidated that P-glycoprotein
(P-gp) at the blood–brain barrier (BBB) limits plasma
oseltamivir penetration into the brain [2,3]. Ro 64-0802
barely diffuses into the brain, and its high hydrophilicity
(cLogP −0.97) was initially considered to be the reason
[3,4]. However, a later study using mice demonstrated that
active efflux at the BBB mediated by organic anion trans-
porter 3 (Oat3) and multidrug resistance protein 4 (Mrp4)
also contributes to the low brain penetration [5]. In
healthy adult humans, the cerebrospinal fluid/plasma ratio
of oseltamivir and Ro 64-0802 were at most 2.1% and
3.5%, respectively, suggesting their low brain penetration
[6]. To investigate the brain penetration in humans and
nonhuman primates, [11C]oseltamivir and [11C]Ro 64-0802
were synthesized as positron emission tomography (PET)
imaging probes [4]. Recent studies demonstrated that the
BBB penetration of [11C]oseltamivir was slightly higher in
adolescent monkeys than that in adults [7,8].
NPAEs have occurred in young patients during rela-
tively early phase after the onset of influenza-like symp-
toms [9]. Furthermore, it was reported that 30% of the
abnormal behaviors of pediatric patients occurred within
2 h after the first use of oseltamivir [9], which is close to
the time of reaching maximum plasma concentrations of
oseltamivir and Ro 64-0802 [6]. It is possible that the im-
mune response leads to the elevation of CNS oseltamivir
concentration by increasing BBB permeability and/or
plasma oseltamivir concentration. Influenza virus infec-
tion strongly activates the immune system and induces
pro-inflammatory cytokines and chemokines systemically.
Some in vitro studies have reported that pro-inflammatory
cytokines alter the integrity of BBB or induce modulation
of efflux transporters [10]. It is reported that the expres-
sion of human carboxylesterase 1 (CES1), responsible for
conversion of oseltamivir to Ro 64-0802 [11], was sup-
pressed by pro-inflammatory cytokine interleukin-6 (IL-6)
in vitro [12]. This highlights the importance of investi-
gating the effect of viral infection on the CNS exposure
of oseltamivir and Ro 64-8082 under therapeutic dosage
in vivo.In the present study, we attempted to evaluate the alter-
ations of CNS uptake of [11C]oseltamivir under similar im-
mune activation of viral infection under therapeutic dose
of oseltamivir medication in living juvenile monkeys using
PET. Immune activation models of Rhesus monkeys have
been developed using synthetic double-stranded RNA,
polyinosine-polycytidylic acid (poly I:C), which induces in-
creasing IL-6 production in the blood [13]. We used an
immune activation model in juvenile monkeys where poly
I:C was administered as an experimental model of viral
infection. Stimulation by the systemic administration
of poly I:C is similar to that by viral infection upstream
of the innate immune response, such as the induction of
pro-inflammatory cytokines [14] and interferon in mon-
keys [15].
The advantages of the use of monkeys over rodents
are the following: (1) their CNS developmental changes
are similar to those in humans; (2) oseltamivir is con-
verted to Ro 64-8082 by hepatic CES in monkeys as in
humans, whereas serum CES activity is high in rodents
[3]; and (3) monkeys are capable of undergoing serial
blood samplings required for estimation of BBB perme-
ability. To achieve therapeutically relevant plasma con-
centrations of oseltamivir and Ro 64-0802 during PET
scan, unlabeled oseltamivir was administered because
the dose of [11C]oseltamivir for PET imaging was approxi-
mately 10 μg/kg. This study is the first to report the
impact of immune activation on oseltamivir brain uptake
in living juvenile monkeys under therapeutic oseltamivir
dosage.Methods
Animals
Three 2-year-old monkeys (Macaca fuscata, one male
and two females; M176, 29 months, 4.0 kg; F175,
32 months, 4.9 kg; and F174, 33 months, 3.9 kg) were
used. One 3-year-old male monkey (Macaca mulatta)
was used to obtain MRI images and baseline [11C]osel-
tamivir PET images for a preliminary experiment. The
animals were kept under pentobarbital anesthesia (i.v.
20 to 25 mg/kg) and warmed by heating pad. Electro-
cardiogram and body temperature, only during poly I:C
treatment condition, were taken with a vital monitoring
system (BP-88 V, OMRON Co., Ltd., Kyoto, Japan). All
the monkeys fully recovered to normal conditions after
each experiment. The monkeys were maintained and
handled in accordance with the guidelines published in
the National Institutes of Health (NIH) Guide for the
Care and Use of Laboratory Animals (NIH, publication
no. 86-23, revised 1987) and the guidelines of the National
Institute of Radiological Sciences (NIRS). The present
study was approved by the Animal Ethics Committee of
NIRS, Chiba, Japan.
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The outline of the experimental protocol is summarized
in Figure 1. In each animal, a set of scans under baseline
and immune activation conditions was performed in this
order, with an interscan interval of 4 weeks or longer for
recovery from blood loss due to arterial blood samplings.
Unlabeled oseltamivir loading
Oseltamivir phosphate (3.2 ± 0.1 mg/kg, Sequoia Research
Products, Pangbourne, UK) dissolved in sterilized distilled
water was intravenously administered 30 min before the
initiation of the PET scan (closed arrow) to maintain
equivalent plasma drug levels under the highest single
therapeutic dose during the PET scan (open arrow). The
dose was determined by the results of our preliminary
experiment and reported human data of the maximum
plasma concentrations (Cmax) of oseltamivir (115 ng/mL)
and Ro 64-0802 (544 ng/mL) [6]. Plasma unlabeled oselta-
mivir and Ro 64-0802 concentrations were measured at 1,
30, and 60 min after [11C]oseltamivir injection to confirm
the establishment of therapeutic plasma concentration
during the PET scan (open arrowheads).
Immune activation by systemic poly I:C injection
In the immune activation studies, 8 mg/kg of poly I:C
(InvitroGen, Carlsbad, CA, USA) dissolved in sterilized
saline was administered intravenously 1 h before the PET
scan (gray arrow). To confirm the induction of immune ac-
tivation, the plasma levels of pro-inflammatory cytokines,
IL-6, interleukin 1β (IL-1β), and tumor necrosis factor α
(TNF-α) were measured just before the administration of
poly I:C, 1 min after the beginning of the PET scan, and at
the end of the scan (gray arrowheads).
Radiosynthesis of [11C]oseltamivir
The radiosynthesis of [11C]oseltamivir is described else-
where [4]. The injected radioactivity, specific radioactiv-
ity, and mass of [11C]oseltamivir at the time of the start
of the PET scan were 466 ± 144 MBq, 3.06 ± 1.04 GBq/










Figure 1 Schematic diagram of the experimental protocol.PET and MRI
The PET scans were performed with a SHR-7700 PET
camera (Hamamatsu Photonics, Hamamatsu, Japan) in
two-dimensional mode, which provides 31 trans-axial
slices 3.6 mm (center-to-center) apart, a 33.1-cm field of
view (FOV), with an axial FOV of 111.6 mm. The head of
the monkey was fixed at the center of the FOV in prone
position. A 50-min transmission scan using a 68Ge-68Ga
source for attenuation correction was performed prior to
the emission scan. [11C]oseltamivir was injected intraven-
ously via the crural vein for 1 min, and a 60-min dynamic
scan (36 frames: 12 × 10 s, 6 × 30 s, 5 × 1 min, 5 × 2 min,
and 8 × 5 min) was started at the time when the gantry
count rate exceeded 100 kcps. The images were recon-
structed by filtered back projection method with a
Hanning filter, resulting in an in-plane reconstructed
resolution of 4.0-mm full width at half maximum.
MRI of the monkey for the preliminary experiment
was performed with SIGNA EXCITE HD at 3.0 T (GE
Medical Systems, Milwaukee, WI, USA). MR imaging con-
sisted of a short-time inversion recovery sequence (STIR,
repetition time (TR) = 5,000 ms, echo time (TE) = 80 ms,
inversion time (TI) = 110 ms, FOV = 100 mm, number of
slices = 52 to 60, slice thickness = 1 mm without slice gap,
512 × 384 acquisition matrix which after reconstruction
was reformatted to a 512 × 512 image matrix, number of
excitations = 6, total acquisition time = 72 to 90 min).Arterial blood sampling
Arterial blood samplings were performed for analyzing
the time courses of plasma [11C]oseltamivir, whole
blood 11C concentrations, and plasma unlabeled oselta-
mivir and Ro 64-0802 concentrations. In the immune
activation study, the pro-inflammatory cytokine levels
were also measured.
In total, 23 arterial blood samples were withdrawn
from the femoral artery. The sampling time points after
the tracer injection were as follows: every 10 s from 10 s
to 1 min, every 15 s from 1 to 3 min, then 3.5, 4, and
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the purpose at each time point.Plasma drug and pro-inflammatory cytokine assay
An aliquot of 0.1-mL plasma was mixed with 2 μg of
esterase inhibitor dichlorvos (1 μL of 200 μg/mL in aceto-
nitrile). The samples were stored at −80°C until used.
Further sample preparation and LC/MS/MS analysis to
determine the concentrations are described elsewhere [3].
Area under the concentration-time curve (AUC) between
1 and 60 min was calculated by the trapezoid method.
Arterial blood samples for pro-inflammatory cytokine
assay were placed on ice, followed by application of
stabilizer (5% v/v). The plasma was separated by refrig-
erated centrifugation (20,000 × g, 3 min, 4°C) and stored
at −80°C until used. Th cytokine levels in plasma were
determined using two-site ELISA according to the direc-
tions of the manufacturer for monkey IL-6, IL-1β, TNF-α
(CKM005, CKM039, CKM009; Cell Sciences, MA, USA).
Optical density was measured at 450 nm by microplate
reader (Tecan Safire2, TECAN, Zurich, Switzerland). The
lower limit of detection for IL-6, IL-1β, and TNF-α was
2 pg/mL each. The test samples and standards were
prepared in duplicate.Plasma [11C]oseltamivir concentration
After taking arterial blood samplings, the radioactivity of
100 μL of whole blood and 200 μL of plasma samples
was measured with a well-type auto-gamma counter
(1480 WIZARD 3″ Gamma Counter, Perkin Elmer, Inc.,
Waltham, MA, USA).
To determine the unmetabolized [11C]oseltamivir frac-
tion in plasma, the samples taken at 1, 3, 5, 10, 20, 40,
and 60 min were subjected to metabolite analysis by
high-performance liquid radiochromatography. An ali-
quot of 0.5-mL plasma was mixed with the same amount
of acetonitrile and then vortexed and centrifuged at
20,000 × g at 4°C for 3 min with a refrigerated centrifuge
for deproteinization. Then, an aliquot of 0.5 mL of the
supernatant was injected into the reverse-phase HPLC
system (JASCO Co., Tokyo, Japan). The analytical column
used was Waters XBridge OST C18 2.5 μm (10 mm×
50 mm) +Waters Xbridge Prep C18 (10 mm× 10 mm)
5-μm Guard Cartridge, the mobile phase was acetonitrile/
50 mM trifluoroacetic acid (22/78) at an isocratic condi-
tion, and the flow rate was 8.0 mL/min (retention time
4.2 min). Effluent radioactivity was detected with a home-
made NaI(Tl) scintillation detector system [16]. The
retention time of the radiochromatography peak of [11C]
oseltamivir was identified by the optical absorption of
standard oseltamivir at a detection wavelength of 254 nm.
The unmetabolized fraction was calculated as the peak
area ratio of unmetabolized [11C]oseltamivir to the totalpeaks detected. Radioactivity recovery in the acetonitrile
supernatant, tested in advance, was 91.4%.
The time course of plasma [11C]oseltamivir concentra-
tions (plasma input function) was calculated as the product
of plasma radioactivity concentration and unmetabolized
plasma [11C]oseltamivir fraction at each time point. At
time points when the unmetabolized fraction was not
measured, it was calculated by linear interpolation of the
measured fractions.
Quantification of plasma-to-brain transfer rate
To estimate the plasma-to-brain transfer rate K1 (mL/
min/cm3), the following model was applied. The radio-
activity concentration of the brain region of interest (ROI)
obtained with PET, CROI(t) (kBq/cm
3), consisted of brain
radioactivity concentration Ct(t) (kBq/cm
3) and vascular
whole blood radioactivity concentration Cw (kBq/mL).
With the use of the fractional blood volume within the
ROI Vb (mL/cm
3), CROI(t) can be expressed as
CROI tð Þ ¼ 1−V bð ÞCt tð Þ þ V bCw tð Þ ð1Þ
Shortly after the intravenous injection, the [11C]oselta-
mivir kinetics in the brain can be described as one-tissue





¼ K1Cp tð Þ; ð2Þ
where Cp is the plasma input function (kBq/mL). Inte-
gration of both sides of Equation 2 and rearrangement
with Equation 1 yield:
CROI tð Þ




Cw tð Þ þ V b ð3Þ
Then, integration plot analysis [17–19] was applied to
estimate K1 and Vb by linear regression up to 3.5 min
with Microsoft Excel 2007 (Redmond, WA, USA;
Figure 2). The delay of plasma input function was deter-
mined by fitting the one-tissue compartment model
using the first 10-min data individually. Image and data
analyses except for integration plot analysis were per-
formed with PMOD 3.0 (PMOD Technologies, Ltd.,
Zurich, Switzerland).
Statistical analysis
The data are presented individually. Due to the small
sample size and gender heterogeneity, statistical test was
not performed in this study.
Figure 2 Integration plot analysis. Linear regression was performed in the shadowed time segment up to 3.5 min (enlarged to the right).
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Physiological conditions
The mean heart rates during PET scans were 155 to
185 bpm and 130 to 189 bpm for baseline and poly I:C
treatment conditions, respectively. Body temperature du-
ring poly I:C treatment condition was kept between
36.5°C and 37.4°C.
Plasma oseltamivir and Ro 64-0802 concentrations
The oseltamivir and Ro 64-0802 concentrations at 1 min
after [11C]oseltamivir injection, corresponding to the up-
take phase, and AUC between 1 and 60 min are shown
in Table 1. Both oseltamivir and Ro 64-0802 concentra-
tions were kept at equivalent levels of the reported cli-
nical concentrations at the highest oral dosing [6] during
the PET scans. Overall, oseltamivir concentrations under
poly I:C treatment were lower than those of the baseline
condition despite the equivalent dosage, whereas the
Ro 64-0802 concentrations were similar.
Plasma pro-inflammatory cytokines
The plasma levels of pro-inflammatory cytokines during
the poly I:C treatment scans are listed in Table 2. AlthoughTable 1 Unlabeled drug concentrations in plasma
Animal Dose (mg/kg) Plasma concentration at 1 min (n
Oseltamivir Ro 64
Baseline Poly I:C Baseline Poly I:C Baseli
M176 3.4 3.3 590 281 622
F175 3.0 3.0 282 222 749
F174 3.2 3.3 343 190 1,004
Mean 3.2 3.2 405 231 792
SD 0.2 0.1 163 46 195there were no significant elevations of TFN-α and IL-1β,
the IL-6 levels of all monkeys were elevated after poly I:C
loading. Therefore, the induction of immune activation by
poly I:C was confirmed in each of the animals.
Brain [11C]oseltamivir PET imaging
The PET images of the baseline and poly I:C treatment
conditions were similar in all monkeys. Figure 3a shows
an MR image of the sagittal plane and the coregistered
PET image averaged between 10 and 60 min post injec-
tion in the preliminary experiment. Radioactivity con-
centration was normalized with injected radioactivity
dose (ID) and body weight, expressed as%ID/cm3 × kg.
Radioactivity in the brain was distributed homogeneously
and was lower than in surrounding muscle except for a
slight accumulation in the ventricle. The coregistered PET
image was used as reference for the determination of ROI
of the juvenile monkeys whose MR images were unavail-
able. For the juvenile monkeys, to minimize the radio-
activity spillover from outside the brain, ventricle, and
major blood vessels, an elliptical ROI was drawn on the
central semiovale level of the summed PET image (10 to
60 min) (Figure 3b) to obtain time-activity curves (TACs).g/mL) AUC (1 to 60 min) (ng/mL ×min)
-0802 Oseltamivir Ro 64-0802
ne Poly I:C Baseline Poly I:C Baseline Poly I:C
494 14,437 10,237 43,252 38,523
727 9,291 7,782 48,849 45,976
1,093 10,667 5,238 65,966 48,924
772 11,465 7,752 52,689 44,474
302 2,664 2,500 11,834 5,361
Table 2 Plasma concentrations of pro-inflammatory cytokines
IL-6 [pg/mL] IL-1β [pg/mL] TNF-α [pg/mL]
Animal Baseline 1 min 60 min Baseline 1 min 60 min Baseline 1 min 60 min
M176 2.74 55.1 739 15.2 12.7 13.3 <2 <2 <2
F175 <2 99.6 525 12.2 7.0 9.3 <2 <2 <2
F174 4.44 14.0 395 51.6 55.1 65.7 <2 <2 <2
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(mean ± SD).
Plasma [11C]oseltamivir kinetics
[11C]oseltamivir was gradually metabolized after its intra-
venous bolus injection as shown in Figure 4a. During the
baseline scan of F174, arterial blood sampling was unavail-
able at 10, 20, and 30 min due to technical troubles. The
time courses of the unmetabolized fractions of F175 and
M176 were similar under baseline conditions, whereas
they fluctuated under the poly I:C treatment. The time
courses of normalized whole blood radioactivity
concentrations and plasma input functions are shown in
Figure 4b,c, respectively. There were no notable diffe-
rences in normalized whole blood radioactivity concen-
trations and plasma input functions between baseline
and poly I:C treatment conditions.
Brain time-activity curves
The individual TACs of the monkey brains are shown in
Figure 5a. The effect of poly I:C treatment on the brain
radioactivity concentrations was quantitatively compared




Figure 3 MR and PET images. Sagittal planes of MRI (a) and the coregist
injection (b) and region of interest (c, d).60 min (Cbrain,40-60min) as shown in Figure 6a. The mean
Cbrain,40-60min values in the monkeys were 0.0033 ±
0.0002% ID/cm3 × kg and 0.0035 ± 0.0003% ID/cm3 × kg
for baseline and after poly I:C treatment, respectively.
The effect of the poly I:C treatment on Cbrain,40-60min
was not notable.
The time courses of the plasma-to-brain concentration
ratio (Kp,brain) were plotted in Figure 5b. The ratio be-
tween 40 and 60 min (Kp,brain,40-60min) was calculated, and
the changes by poly I:C treatment are shown in Figure 6b.
The mean Kp,brain,40-60min values of the three monkeys
were 0.58 ± 0.07 for baseline and 0.65 ± 0.14 for poly I:C
treatment conditions. The effect of poly I:C treatment on
Kp,brain,40-60min was not notable.
Plasma-to-brain [11C]oseltamivir transfer rate
A typical example of the integration plot is shown in
Figure 2. The linear segment in the first few minutes con-
firmed a negligible efflux from the brain within the period.
The mean K1 values of the three monkeys were 0.0049 ±
0.0004 mL/min/cm3 for baseline and 0.0053 ± 0.0005 mL/
min/cm3 for the poly I:C treatment. The K1 values at
baseline and after poly I:C treatment are compared ind
c
ered averaged PET image from 10 to 60 min after [11C]oseltamivir
ab c
Figure 4 [11C]oseltamivir kinetics in blood and plasma. The time course of unmetabolized plasma fraction (a), whole blood TACs (b), and
plasma input functions (c) in logarithmic scale. The inset graphs correspond to the curves at early times (0 to 3 min). The data are presented
individually as baseline (open symbols with solid line) and poly I:C treatment (filled symbols with dashed line) scans.
Figure 5 Brain time-activity curves (TACs). (a) Brain TACs plotted in logarithmic scale of individual monkey of baseline and poly I:C treatment
scans. Brain concentrations normalized with injected radioactivity (ID) and body weight. The inset graph corresponds to TACs at early
post-injection times (0 to 3 min). (b) The time courses of brain-to-plasma radioactivity concentration ratio are plotted individually. The symbols
and lines correspond to individual animals and conditions as in Figure 4.
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Figure 6 The changes of brain [11C]oseltamivir uptake by poly I:C. (a) Normalized brain concentration, (b) brain-to-plasma [11C]oseltamivir
concentration ratio, and (c) plasma-to-brain transfer rate (K1) of individual monkeys (solid lines) and mean (dashed lines) are shown.
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ment. The estimated Vb ranged from 0.022 to 0.028 mL/
cm3. This value was comparable to the reported cerebral
blood volume in monkeys of 0.035 mL/cm3 [20].
Discussion
In the present study, we examined the effect of innate
immune activation on the CNS uptake of oseltamivir at
its clinically relevant plasma concentrations using [11C]
oseltamivir and PET in living juvenile monkeys. We used
intravenous poly I:C administration to activate the im-
mune response to simulate viral infection. Poly I:C
stimulates toll-like receptor 3 (TLR3), one of the innate
immune-recognition receptors, whereas influenza virus
is recognized by TLR7. Both TLRs are expressed in
endosome, and their stimulations result in the induction
of pro-inflammatory cytokines via different signaling path-
ways [21]. This study demonstrated an immediate increase
of plasma IL-6 after poly I:C treatment, while no alter-
ations were observed in TNF-α and IL-1β in the first 2 h
(Table 2). The elevation of plasma IL-6 has been reported
as the common feature in influenza patients including
children [22,23], and therefore, the immune responses to
poly I:C and influenza virus are similar despite differences
in the signaling pathways. From the rapid elevation of
plasma IL-6 throughout the experimental period, the
immune activation model in this study was considered
to simulate a part of the innate immune response to in-
fluenza virus infection. The lack of elevation of body
temperature is considered to be due to the hypothermic
effect of the applied anesthesia.
In the quantification of the CNS concentration of low
BBB permeable radiolabeled ligand, the linearity of mea-
sured radioactivity concentration from a low level and
the contribution of intravascular radioactivity must be
considered significant. The lowest decay-uncorrected
radioactivity concentration in the brain was approxi-
mately 0.2 kBq/cm3. The PET scanner used in this study
has a linearity between 0.05 and 50 kBq/cm3. Therefore,the brain concentration was accordingly quantified with
the PET scanner. Nevertheless, in consideration of the
noise, we placed ROI on the central semiovale where
the largest ROI was available for better statistics.
Regarding intravascular radioactivity, both the TACs of
blood and brain peaked at about 1 min simultaneously,
as shown in Figures 4b and 5a. At this point, the peak of
blood radioactivity was approximately 1% ID/mL × kg
(Figure 4b). Using Vb of 0.025 mL/cm
3 estimated by in-
tegration plot analysis, the vascular radioactivity at the
peak was estimated to be about 0.025% ID/cm3 × kg.
This value is close to the peak values of the brain TACs
(Figure 5a). At later times, between 40 and 60 min post
injection, the mean normalized blood concentration of
poly I:C treatment condition was 0.025% ID/mL × kg.
Using Vb of 0.025 mL/cm
3, the vascular radioactivity in
the brain ROI can be estimated as 0.000625% ID/cm3 ×
kg, corresponding to 18% of Cbrain,40-60min (0.0035% ID/
cm3 × kg). This indicates that the contribution of vascu-
lar radioactivity at later times became less than in the
first few minutes. To remove the contribution of intra-
vascular radioactivity from the measured brain concen-
tration, Equation 1 can be applied to estimate the net
brain concentration Ct(t) using Vb obtained from inte-
gration plot analysis (Equation 3). By this intravascular
radioactivity correction (CBV-correction), Cbrain,40-60min
and Kp, brain overall became 15% less than the un-
corrected values, but the changes of Cbrain,40-60min and
Kp,brain values by poly I:C treatment were very similar.
The individual CBV-corrected results are shown in
Additional file 1.
With respect to the plasma-to-brain transfer rate, the
estimated K1 values were considerably lower than mon-
key CBF, which is approximately 0.5 mL/min/g [20], and
therefore, the extraction fraction (E) is approximated to
0.01 using the relationship K1 = E∙CBF. According to the
Crone-Renkin equation [24,25], the penetration of [11C]
oseltamivir across the BBB is in a diffusion-limited man-
ner, and therefore, K1 is not considered to reflect CBF.
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PET includes both [11C]oseltamivir and [11C]Ro 64-0802.
The latter is less BBB-permeable than oseltamivir, so the
radioactive metabolite [11C]Ro 64-0802 penetration into
the CNS is less likely. But, the fact that the immunoreactiv-
ity of CES1 was detected in human brain endothelial cells
[26] suggests that [11C]Ro 64-0802 can be formed from
[11C]oseltamivir in brain capillary endothelial cells. Al-
though Oat3 and Mrp4 facilitate removal of Ro 64-0802,
which is formed in the endothelial cells from the brain to
the blood [5], part of the radioactivity in the brain may be
attributed to [11C]Ro 64-0802, but the major portion of
CNS radioactivity can be ascribed to [11C]oseltamivir.
With the use of CNS concentration measured with
PET, one can roughly estimate the CNS drug concen-
tration under therapeutic dose. Using Cbrain,40-60min of
0.0035% ID/cm3 × kg, the CNS oseltamivir concentration
at a therapeutic dose of 2 mg/kg can be approximated as
0.22 μM. Or, with the use of plasma-to-brain ratio
Kp,brain,40-60min and the reported Cmax in a clinical study
of 115 ng/mL [6], the CNS concentration can be esti-
mated as high as 0.37 μM. It has been reported that no
inhibitory effect against recombinant human neurami-
dases was detected up to 1 mM of both oseltamivir and
Ro 64-0802 [24]. This report also demonstrated that no
relevant inhibitory effect against various molecular tar-
gets of neurotransmitter system was observed up to
3 μM for both oseltamivir and Ro 64-0802 [27]. Alterna-
tively, a previous study of electrophysiology experiments
using mouse brain reported that the pharmacological
effect was detected at ED50 of 10.2 μM for oseltamivir
and 0.7 μM for Ro 64-0802 [28]. The CNS concentra-
tions estimated with the PET data are lower than these
reported concentrations.
The normalized brain concentration at later times and
the transfer rate (K1 or CLuptake, brain) were about half of
those of a previous report using adolescent monkeys [8].
Several factors including different anesthesia can be con-
sidered. First, the monkeys used in this study were in a
later developmental stage with almost double the body
weight of those used in the previous report. Therefore,
the different developmental stage would be a reason for
the difference. Second, the values of the parameters are
considered to depend on the placing of the ROI. We
chose the central semiovale. As described previously,
the radioactivity was considered relatively lower than in
other regions. Third, the number of blood samples for
input function used for integration plot analysis can be
a factor that causes different results in calculated trans-
fer rates. In this study, we took samples 12 times, with
the shortest interval being 10 s, between 10 s and
2.5 min, whereas four samples with the shortest interval
of 30 s were collected between 30 s and 2.5 min in the
previous study.One of the limitations of this study was the small
sample size and gender heterogeneity. For this reason,
statistical evaluation of changes in oseltamivir brain up-
take by poly I:C treatment could not be strictly performed.
There have been no studies to test the alterations of a
drug penetration into the CNS by immune activation
in vivo in nonhuman primates under therapeutic dose.
PET imaging of radiolabeled drug in a monkey model of
immune activation is advantageous for assessing the
changes in drug distribution by viral infection directly
in vivo.
Conclusions
[11C]oseltamivir uptake into the CNS in a juvenile monkey
model did not show notable change by immune activation
induced by poly I:C administration under clinically rele-
vant plasma levels of oseltamivir and its active metabolite
Ro 64-0802.
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